Supriya Lifescience Ltd - 543434 - Reg. 34 (1) Annual Report.
Please find attached herewith Annual Report of F.Y. 2022-23.06-09-2023
06-09-2023
Supriya Lifescience Ltd - 543434 - Business Responsibility and Sustainability Reporting (BRSR)
Please find attached herewith BRSR of F.Y. 2022-23.06-09-2023
Supriya Lifescience Ltd - 543434 - Notice Of The 15Th Annual General Meeting
We wish to inform you that 15th Annual General Meeting of the Company scheduled to be held on September 29, 2023 at 03:00 p.m. through VC/OAVM.06-09-2023
Supriya Lifescience Ltd - 543434 - Intimation Of Record Date For The Purpose Of Dividend & Annual General Meeting
Intimation of Record date.05-09-2023
Supriya Lifescience Ltd - 543434 - Intimation Of Book Closures Date For The Purpose Of Dividend & Annual General Meeting
Intimation of Book Closures date.05-09-2023
Supriya Lifescience Ltd - 543434 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Please find attached herewith Newspaper Publication.04-09-2023
Supriya Lifescience Ltd - 543434 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Please find the attachment.24-08-2023
Supriya Lifescience Ltd - 543434 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to the relevant provisions of the SEBI Listing Regulations, we would like to inform you that the officials of our Company, Supriya Lifescience Limited ('Company') will be interacting with Analyst/Institutional Investors on August 21, 2023 via video conference.17-08-2023
Supriya Lifescience Ltd - 543434 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Please find enclosed herewith Earning Call Transcript.08-08-2023
Q1FY24 Quarterly Result Announced for Supriya Lifescience Ltd.
Pharmaceuticals company Supriya Lifescience announced Q1FY24 results: Total revenue of Rs 134.9 crore in Q1FY24, as compared to Rs 103.7 crore in Q1FY23 Total PAT of Rs 28.51 crore in Q1FY24, as compared to Rs 25.25 crore in Q1FY23 Reported PAT margin of 22% Reported Gross profit of 64% EBITDA reported Rs 44.49 crore in Q1FY24, as compared to Rs 31.25 crore in Q1FY23 Healthy EBITDA margin of 34% reported in Q1FY24 Asian market contributed over 40% of the business, whereas Europe contributed 35% Satish Wagh, Chairman and Managing Director, Supriya Lifescience, commenting on their results said, “The company has been resilient to the global economic conditions and has delivered a strong comeback. Our strategic business initiatives of deeper penetration in existing markets and tapping new markets, backed by our world-class R&D; capabilities, have been the key growth drivers for our business. The demand from regulated markets like Europe, North America, and Latin America have surged and come back to normalcy.” Result PDF04-08-2023